1. Is Sun Pharmaceutical Industries Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Sun Pharmaceutical Industries Ltd is a good quality company.
2. Is Sun Pharmaceutical Industries Ltd undervalued or overvalued?
The key valuation ratios of Sun Pharmaceutical Industries Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Sun Pharmaceutical Industries Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Sun Pharmaceutical Industries Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||22.2%||24.4%||16.7%||13.5%||14.5%||6%||7.4%||7.3%||10.8%||12.7%||-|
|Value Creation Index ⓘ||1.0||1.2||0.5||0.2||0.3||-0.5||-0.3||-0.4||-0.0||0.1||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||42.3%||70.3%||2.6%||11.4%||-15.6%||10%||13%||2%||15.4%||-|
|Adj EPS ⓘ||16.3||23.4||22.5||21.8||27.8||11.3||15.1||16.4||24.5||27.4||16.2|
|YoY Gr. Rt. %||-||43.5%||-3.8%||-2.9%||27.4%||-59.3%||33.2%||8.6%||49.8%||11.9%||-|
|BVPS (₹) ⓘ||72.4||89.4||123.5||137||152.7||159.7||172.6||188.7||193.7||200.1||208.8|
|Adj Net Profit ⓘ||3,370||4,836||4,653||5,250||6,664||2,713||3,616||3,925||5,882||6,579||3,889|
|Cash Flow from Ops. ⓘ||3,357||3,959||5,616||6,686||7,082||3,907||2,196||6,555||6,170||8,985||-|
|Debt/CF from Ops. ⓘ||0.1||0.7||1.6||1.3||1.4||2.7||4.8||1.3||0.6||0.1||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||6%||-0.3%||22.1%||11.9%|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||24.8||28.9||21.1||17.9||19.1||7.2||9.1||9.1||12.8||13.9||7.9|
|Op. Profit Mgn % ⓘ||43.7||44.5||28.9||30.8||31||21.1||22.1||21.3||25.3||26.5||26|
|Net Profit Mgn % ⓘ||34.1||34.7||20.5||22.6||24.1||12.1||14.3||13.2||15.7||17.4||9.9|
|Debt to Equity ⓘ||0||0.1||0.4||0.3||0.3||0.3||0.3||0.2||0.1||0||-|
|Working Cap Days ⓘ||205||192||189||243||239||163||154||148||146||136||0|
|Cash Conv. Cycle ⓘ||81||59||54||78||81||12||24||45||47||44||0|
Net Profit is growing at healthy rate in last 3 years 22.08%
Sales growth is good in last 4 quarters at 11.29%
Return on Equity has declined versus last 3 years average to 7.90%
Sales growth has been subdued in last 3 years 9.97%
|TTM EPS (₹)||4.4||16.2|
|TTM Sales (₹ Cr.)||16,729||39,401|
|BVPS (₹.) ⓘ||106.7||208.8|
|Reserves (₹ Cr.) ⓘ||25,360||49,867|
|From the Market|
|52 Week Low / High (₹)||733.95 / 966.90|
|All Time Low / High (₹)||1.65 / 1200.70|
|Market Cap (₹ Cr.)||2,20,931|
|Equity (₹ Cr.)||239.9|
|Face Value (₹)||1|
|Industry PE ⓘ||37.9|
Sun Pharmaceutical Industries established in 1983 with five psychiatry products and a two person marketing team. Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. It provide high-quality, affordable medicines trusted by healthcare professionals and patients in many countries worldwide. Sun Pharma is also India’s largest and pharmaceutical company. Its global presence is supported by several manufacturing facilities across few continents. In the US market which contributes a significant share of its revenues, the company is the leader in the generic dermatology segment. It has strong capabilities in developing generic and complex products with a robust pipeline of many ANDAs, including high value First-to-File (FTF) opportunities. It has an established presence in Europe and key high-growth Emerging Markets (EM) like Russia, Romania, South Africa, Brazil and Malaysia. The company’s primary focus is to in-license generic and differentiated generic products that are close to commercialization or in advanced stage of development for North America, Western Europe and Japan markets.
The company is market leader in India and it is interested in partnerships for late stage and/or marketed opportunities complementary to its commercial footprint or expansion within its core areas of focus in India. These include CNS disorders, Cardiology, Diabetes and Metabolic disorders, Gastroenterology, Ophthalmology, Oncology, Pain, Rheumatology, Allergy, Asthma and Inflammation and Gynecology. Its focus is for NCEs, NBEs, NDDS based differentiated products, Biosimilars, Proprietary Technology Barrier Products which provide it the first mover advantage in India. The company’s leadership position in India allows it to offer significant value to innovator companies who want to partner with a dynamic and leading company, capable of successfully marketing its assets and willing to give the right priority to in-licensed or partnered projects.
Business area of the company
The company is among the largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in many countries across the world, at affordable prices.
Establishment & Growth
Acquisitions & Alliances
Research & Manufacturing
Products & Innovations